DE3752123D1 - Derivate des physiologisch aktiven mittels k-252 - Google Patents

Derivate des physiologisch aktiven mittels k-252

Info

Publication number
DE3752123D1
DE3752123D1 DE3752123T DE3752123T DE3752123D1 DE 3752123 D1 DE3752123 D1 DE 3752123D1 DE 3752123 T DE3752123 T DE 3752123T DE 3752123 T DE3752123 T DE 3752123T DE 3752123 D1 DE3752123 D1 DE 3752123D1
Authority
DE
Germany
Prior art keywords
derivatives
active agent
physiologically active
physiologically
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3752123T
Other languages
English (en)
Other versions
DE3752123T2 (de
Inventor
Chikara Murakata
Akira Sato
Mitsuru Takahashi
Eiji Kobayashi
Makoto Morimoto
Shiro Akinaga
Tadashi Hirata
Kenichi Mochida
Hiroshi Kase
Koji Yamada
Kazuyuki Iwahashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Application granted granted Critical
Publication of DE3752123D1 publication Critical patent/DE3752123D1/de
Publication of DE3752123T2 publication Critical patent/DE3752123T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE3752123T 1987-03-09 1987-03-09 Derivate des physiologisch aktiven mittels k-252 Expired - Lifetime DE3752123T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP1987/000144 WO1988007045A1 (en) 1987-03-09 1987-03-09 Derivatives of physiologically active substance k-252

Publications (2)

Publication Number Publication Date
DE3752123D1 true DE3752123D1 (de) 1997-11-06
DE3752123T2 DE3752123T2 (de) 1998-05-14

Family

ID=13902623

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3752123T Expired - Lifetime DE3752123T2 (de) 1987-03-09 1987-03-09 Derivate des physiologisch aktiven mittels k-252

Country Status (4)

Country Link
US (1) US4923986A (de)
EP (1) EP0303697B1 (de)
DE (1) DE3752123T2 (de)
WO (1) WO1988007045A1 (de)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5438050A (en) * 1988-02-06 1995-08-01 Godecke Aktiengesellschaft Indolocarbazole derivatives, processes for their preparation and compositions containing them
US5015578A (en) * 1989-03-23 1991-05-14 Bristol-Myers Squibb Company BMY-41950 antitumor antibiotic
DE3924538A1 (de) * 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung
US5166204A (en) * 1989-11-01 1992-11-24 Toyama Chemical Co., Ltd. Isoindole derivatives and salts thereof and antitumor agent comprising the same
US5618809A (en) * 1989-12-14 1997-04-08 Schering Corporation Indolocarbazoles from saccharothrix aerocolonigenes copiosa subsp. nov SCC 1951 ATCC 53856
WO1991009034A1 (en) * 1989-12-14 1991-06-27 Schering Corporation Indolocarbazoles from saccharothrix aerocolonigenes subsp. copiosa subsp. nov. scc 1951 atcc 53856
US5811396A (en) * 1991-03-14 1998-09-22 The United States Of America As Represented By The Department Of Health And Human Services TRK tyrosine kinase receptor is the physiological receptor for nerve growth factor
MX9201643A (es) * 1991-04-11 1992-10-01 Schering Corp Agentes contra tumores y anti-psoriasicos.
CA2123096A1 (en) 1991-11-08 1993-05-13 Beat J. Knusel Compositions containing k-252 compounds for potentiation of neurotrophin activity
US5591842A (en) * 1991-11-29 1997-01-07 Banyu Pharmaceutical Co., Ltd. Indolopyrrolocarbazole derivatives
US5668271A (en) * 1991-11-29 1997-09-16 Banyu Pharmaceutical Co., Ltd. Indolopyrrolocarbazole derivatives
US5344926A (en) * 1992-06-22 1994-09-06 Kyowa Hakko Kogyo Co., Ltd. Process for producing staurosporine derivatives
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5621101A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
US5621100A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
WO1994004541A2 (en) * 1992-08-12 1994-03-03 The Upjohn Company Protein kinase inhibitors and related compounds combined with taxol
DE69331228T4 (de) * 1992-09-21 2002-09-05 Kyowa Hakko Kogyo Kk Heilmittel für thrombozytopenia
EP1447098A3 (de) 1993-01-28 2005-06-29 Boston Scientific Limited Therapeutische Inhibitoren der glatten Gefässmuskulaturzellen
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
ATE165097T1 (de) * 1993-05-28 1998-05-15 Cephalon Inc Anwendung von indolocarbazol-derivaten zur behandlung von prostataerkrankungen
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
EP0657411B1 (de) * 1993-12-07 1999-06-09 Eli Lilly And Company Synthese von Bisindolylmaleimiden
US5541347A (en) * 1993-12-07 1996-07-30 Eli Lilly And Company Synthesis of bisindolylmaleimides
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US5723456A (en) * 1993-12-07 1998-03-03 Eli Lilly & Company Therapeutic treatment for cardiovascular diseases
US5843935A (en) * 1993-12-07 1998-12-01 Eli Lilly And Company Protein kinase C inhibitors
PL182124B1 (pl) * 1993-12-07 2001-11-30 Lilly Co Eli Nowe zwiazki oraz srodek farmaceutyczny przeznaczony do leczenia powiklan cukrzycowych lub do leczenia nowotworów PL PL PL PL PL PL PL PL
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
PT817627E (pt) * 1993-12-23 2005-07-29 Lilly Co Eli Inibidores da proteina cinase c
AU1911095A (en) * 1994-02-18 1995-09-04 Cephalon, Inc. Aqueous indolocarbazole solutions
US5604219A (en) * 1994-03-18 1997-02-18 Kyowa Hakko Kogyo Co., Ltd. Indolocarbazole derivatives that stimulate platelet production
CA2144940A1 (en) * 1994-03-18 1995-09-19 Chikara Murakata Therapeutic agent for thrombocytopenia and indolocarbazole derivatives
US5922860A (en) * 1994-05-09 1999-07-13 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyrrolocarbazole derivatives
US5804564A (en) * 1994-05-09 1998-09-08 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyrrolocarbazole derivatives
US5481003A (en) * 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
US5491242A (en) * 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
US5475110A (en) * 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5594009A (en) * 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5591855A (en) * 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5650407A (en) * 1995-04-05 1997-07-22 Cephalon, Inc. Selected soluble esters of hydroxyl-containing indolocarbazoles
US5686444A (en) * 1995-04-05 1997-11-11 Cephalon, Inc. Selected soluble esters of hydroxyl-containing indolocarbazoles
WO1997007081A2 (en) * 1995-08-11 1997-02-27 Yale University Glycosylated indolocarbazole synthesis
US5808060A (en) * 1995-12-11 1998-09-15 Cephalon, Inc. Fused isoindolones
US5616724A (en) * 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
US6875865B1 (en) 1996-06-03 2005-04-05 Cephalon, Inc. Selected derivatives of K-252a
UA67725C2 (en) 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
NZ333441A (en) 1996-06-25 1999-05-28 Cephalon Inc Use of k-252a derivatives for the treatment of peripheral or central nerve disorders, and cytokine overproduction
ATE278397T1 (de) 1997-03-31 2004-10-15 Boston Scient Ltd Verwendung von cytoskelettinhibitoren zur vorbeugung der restenose
HUP0003194A3 (en) † 1997-08-15 2003-03-28 Cephalon Inc West Chester Use of tyrosine kinase inhibitor in synergic pharmaceutical composition treating prostate cancer
DK1044203T3 (da) 1997-12-31 2003-07-14 Cephalon Inc 3'-epimere K-252a-derivater
US6127401A (en) 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6013646A (en) * 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US7795246B2 (en) * 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
JP2002525329A (ja) * 1998-09-25 2002-08-13 セフアロン・インコーポレーテツド 感覚毛細胞及び蝸牛ニューロンへの損傷を予防する／処置するための方法
US6841567B1 (en) 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
JP2000290184A (ja) * 1999-04-01 2000-10-17 Kyowa Hakko Kogyo Co Ltd 経鼻投与製剤
US6284783B1 (en) 1999-06-09 2001-09-04 The Uab Research Foundation Use of bisindolylmaleimide compounds to induce Fas-mediated apoptosis
WO2001010440A1 (en) * 1999-08-09 2001-02-15 Trustees Of Dartmouth College COMPOSITIONS AND METHODS TO ENHANCE CANCER CHEMOTHERAPY IN p53 DEFECTIVE TUMORS
US6399780B1 (en) * 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
US7129250B2 (en) * 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
CA2308994A1 (en) * 2000-05-19 2001-11-19 Aegera Therapeutics Inc. Neuroprotective compounds
US7018999B2 (en) * 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
CA2393720C (en) * 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
CA2571421A1 (en) 2004-06-24 2006-01-05 Nicholas Valiante Compounds for immunopotentiation
CA2604408A1 (en) * 2005-04-20 2006-10-26 Abbott Laboratories Fermentation broth extraction of k-252a
PT1919979E (pt) 2005-08-25 2014-03-07 Creabilis Therapeutics Spa Polímeros conjugados de k-252a e seus derivados
EP1968984A1 (de) * 2005-12-09 2008-09-17 Abbott Laboratories Lestaurtinibkristallform 1, kristallines lestaurimib-anhydrat und amorphes lestaurimib
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
US20070208173A1 (en) * 2006-03-02 2007-09-06 Ron Christopher Kelly Crystalline hydrates of cefdinir calcium salt
AR060358A1 (es) 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
US20100179318A1 (en) * 2007-01-11 2010-07-15 Abbott Laboratories Process to make lestaurtinib
US20080177062A1 (en) * 2007-01-15 2008-07-24 Abbott Laboratories CRYSTALLINE K-252a BIS(N,N' DIMETHYLFORMAMIDATE)
US20080177063A1 (en) * 2007-01-16 2008-07-24 Abbott Laboratories CRYSTALLINE K-252b, SODIUM SALT, HYDRATE
US20080299215A1 (en) * 2007-05-29 2008-12-04 Protia, Llc Deuterium-enriched lestaurtinib
WO2009067221A2 (en) * 2007-11-20 2009-05-28 Cephalon, Inc. Microemulsion containing indolocarbazole compound and dosage forms containing the same
KR20100093129A (ko) 2007-12-20 2010-08-24 노파르티스 아게 Ｐｉ ３ 키나제 억제제로서 사용되는 티아졸 유도체
WO2009091594A1 (en) * 2008-01-16 2009-07-23 Cephalon, Inc. Crystalline forms of lestaurtinib
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
PA8855801A1 (es) 2008-12-23 2010-07-27 Sintesis de nucleosidos de purina
EP2376514A2 (de) * 2008-12-23 2011-10-19 Pharmasset, Inc. Nukleosidanaloga
AR074897A1 (es) 2008-12-23 2011-02-23 Pharmasset Inc Fosforamidatos de nucleosidos
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
US8859756B2 (en) 2010-03-31 2014-10-14 Gilead Pharmasset Llc Stereoselective synthesis of phosphorus containing actives
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
JP5963777B2 (ja) 2011-01-31 2016-08-03 ノバルティス アーゲー 新規ヘテロ環誘導体
CN104039790B (zh) 2011-10-28 2016-04-13 诺华股份有限公司 嘌呤衍生物及它们在治疗疾病中的应用
BR112014028420A2 (pt) 2012-05-16 2017-09-19 Novartis Ag regime de dosagem para um inibidor de quinase pi-3
JP2016539149A (ja) 2013-12-06 2016-12-15 ノバルティス アーゲー アルファ−アイソフォーム選択的ホスファチジルイノシトール３−キナーゼ阻害剤の投薬レジメン
AU2016347881A1 (en) 2015-11-02 2018-05-10 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
US11993611B2 (en) * 2020-07-02 2024-05-28 Baylor University Indolocarbazole analogs of staurosporine and methods of synthesis thereof
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041489A (ja) * 1983-08-12 1985-03-05 Kyowa Hakko Kogyo Co Ltd 新規生理活性物質ｋ―２５２
JPS60185719A (ja) * 1984-03-06 1985-09-21 Ajinomoto Co Inc 抗腫瘍剤
JPS61176531A (ja) * 1985-01-31 1986-08-08 Kyowa Hakko Kogyo Co Ltd 新規物質ｋｔ５５５６
JPS61268687A (ja) * 1985-05-24 1986-11-28 Meiji Seika Kaisha Ltd Ｓｆ−２３７０物質誘導体およびその製造法
JPS62120388A (ja) * 1985-11-19 1987-06-01 Meiji Seika Kaisha Ltd Ｓｆ−２３７０物質ハロゲン化誘導体とその製造法
JPS62155284A (ja) * 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPS62155285A (ja) * 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPS62164626A (ja) * 1986-01-17 1987-07-21 Meiji Seika Kaisha Ltd 降圧および利尿剤
JPS62240689A (ja) * 1986-04-07 1987-10-21 Meiji Seika Kaisha Ltd Ｓｆ−２３７０物質誘導体及びその製法

Also Published As

Publication number Publication date
US4923986A (en) 1990-05-08
EP0303697B1 (de) 1997-10-01
DE3752123T2 (de) 1998-05-14
EP0303697A1 (de) 1989-02-22
WO1988007045A1 (en) 1988-09-22
EP0303697A4 (de) 1990-05-14

Similar Documents

Publication Publication Date Title
DE3752123D1 (de) Derivate des physiologisch aktiven mittels k-252
NO883974L (no) Fremgangsmaate for fremstilling av terapeutiske aktive tetrahydro-hydroksypyranon-derivater.
NO871266L (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinazolin-derivater.
NO904694D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazolderivater.
NO864126D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyridon-derivater.
NO901684L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 3-substituerte-2-oksindol-derivater.
NO894630D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinuklidin-derivater.
NO914667D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive arylderivater
NO870526D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive dikloranilin-derivater.
NO874032D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive catecholderivater.
NO169014C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive distamycinderivater
NO864130D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive karboksamid-derivater.
NO875488L (no) Fremgangsmaate for fremstilling av terapeutisk aktive alkansulfonanilid-derivater.
NO862372D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinolonderivater.
NO900697D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive acetamid-derivater.
NO891723L (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinazolin-derivater.
NO884176L (no) Fremgangsmaate for fremstilling av terapeutisk aktive amidinoderivater.
NO167739C (no) Anologifremgangsmaate for fremstilling av terapeutisk aktive ginkolid-derivater.
NO865012L (no) Fremgangsmaate for fremstilling av terapeutisk aktive benzazepin-derivater.
NO881884D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrrolidin-derivater.
NO864101L (no) Fremgangsmaate for fremstilling av terapeutisk aktive dikloranilinderivater.
NO871907D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive alkenamid-derivater.
NO900972D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive naftalen-derivater.
NO900942D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive azacyklooktadien-derivater.
NO890724D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive tetraazaacenaftylen-derivater.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition